Milano, 4 maggio 2022 – Enthera Pharmaceuticals (“Enthera”), azienda biotecnologica che sviluppa farmaci biologici “first in class” per alcune malattie autoimmuni nelle quali è coinvolto un nuovo meccanismo di apoptosi, annuncia oggi la nomina di Aled Williams a amministratore delegato e membro del suo Consiglio di Amministrazione. Aled ha oltre venticinque anni di esperienza in posizioni […]
Milan, Italy, 4 May 2022 – Enthera Pharmaceuticals (“Enthera”), a biotech company developing first-in-class biologics for selected autoimmune conditions based on the discovery of a novel apoptosis pathway, today announces the appointment of Aled Williams as Chief Executive Officer and member of its Board of Directors. Aled has over twenty-five years of experience as a senior […]
New publication titled ‘The IGFBP3/TMEM219 pathway regulates β-cell homeostasis’ published in leading peer-review journal, Nature Communications The research confirms that the recently discovered ‘IGFBP3/TMEM219’ apoptosis pathway plays a key role in beta cell homeostasis, and has the potential to be utilized as a new therapeutic approach for type 1 diabetes Enthera aims to leverage the IGFBP3/TMEM219 pathway to […]
Antonio Speziale joins Enthera with drug development and commercialization experience from roles at Galapagos, Shire, Novartis, Genzyme and Wyeth Milan, Italy, 4 October 2021 – Enthera Pharmaceuticals (“Enthera”), a biotech company developing first-in-class biologics for selected autoimmune conditions based on the discovery of a novel apoptosis pathway, has appointed Antonio Speziale as Chief Medical Officer. […]
The OpenZone drug discovery unit will be used to support Enthera’s new discovery program and accelerate its mission to identify new treatments for intractable autoimmune diseases Milan, Italy, 7 July 2021 – Enthera Pharmaceuticals (“Enthera”), a biotech company developing first-in-class biologics for selected autoimmune conditions based on the discovery of a novel apoptosis pathway, today […]
Milan, Italy, 1 April 2021 – Enthera Pharmaceuticals (“Enthera”), a biotech company developing novel disease-modifying biologics that re-establish stem cell capabilities to treat specific autoimmune diseases, today announces the appointment of Claudia Nardini as Vice President of Research and Development to support the Company’s manufacturing and regulatory divisions. Claudia has 25 years of experience in […]
The Roche Venture Fund joins international investor syndicate, including co-lead investors Sofinnova Partners and AbbVie Ventures Funds to be used to advance restorative therapy for type 1 diabetes and inflammatory bowel disease Largest international VC-backed Series A financing round for a biotech in Italy to date and first ever venture investment in an Italian company […]
Milan, Italy, 3 December 2020 – Enthera Pharmaceuticals (“Enthera”), a biotech company developing disease-modifying biologics to transform the therapeutic paradigm of specific autoimmune conditions by re-establishing stem cell capabilities in a non-traditional way, announces that it has appointed Kazumi Shiosaki to its Board of Directors, and Lisa Olson to its Scientific Advisory Board.
Milan, Italy – Enthera Pharmaceuticals (“Enthera”), a biotech company developing disease-modifying biologics to transform the therapeutic paradigm of specific autoimmune conditions by re-establishing stem cell capabilities in a non-traditional way, today announces the completion of a €28 million Series A financing round.
Enthera, an innovative Italian start-up dedicated to the research and development of innovative therapeutics to treat Type 1 Diabetes and gastrointestinal diseases, received an investment of €4 million led by Sofinnova along with the JDRF T1D Fund (the venture capital fund of the authoritative US JDRF Foundation dedicated to promoting research on Type 1 Diabetes), the accelerator BiovelocITA and its shareholders.
